Hadlima Solution
Product Images NDC 50090-6706

Product Visual Gallery

This gallery contains 68 technical images submitted to the FDA as part of the official labeling for Hadlima (NDC 50090-6706). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph comparing the percentage of ACR20 responders over time (weeks) between two groups: one receiving 40 mg every other week of the drug and a placebo group. The x-axis represents time in weeks, and the y-axis represents the percent of responders, showing higher response rates in the 40 mg group throughout the study period.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing the percentage of ASAS 20 response over time (weeks) comparing placebo and adalimumab treatment groups. The x-axis represents time in weeks (0 to 26), and the y-axis shows the percentage response (0% to 70%). Two lines depict outcomes for placebo (dashed line) and adalimumab (solid line) groups, with adalimumab showing a higher response over the study period.*

FDA Label Image

Samsung Logo (Image 03)

FDA Label Image

Organon Logo (Image 04)

The label states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Samsung Logo (Image 05)

FDA Label Image

Organon Logo (Image 06)

Label showing the manufacturer information for HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. Manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA. The label features the Organon & Co. logo.*

FDA Label Image

Figure A (Prefilled Syringe)

Illustration labeled Figure A showing a syringe with parts identified, including the needle cap, body with window, flange, and plunger. The image depicts the components of a syringe typically used for subcutaneous injection.*

FDA Label Image

Refrigerator (Image 08)

The image shows the HADLIMA 40 mg/.8 mL solution for subcutaneous injection packaging. The label displays the product name HADLIMA, active ingredient adalimumab-bwwd, and indicates it is a human prescription drug. The labeler is A-S Medication Solutions. The packaging is simple and primarily white with some blue accents.*

FDA Label Image

Light (Image 09)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The carton displays the proprietary name HADLIMA prominently, with the generic name adalimumab-bwwd below it. The label includes dosage strength and route information, along with the manufacturer A-S Medication Solutions. The package appears to be a small box designed to contain the medication.*

FDA Label Image

Caution (Image 10)

The image shows a box for HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, and states the product strength and form. The labeler listed is A-S Medication Solutions.*

FDA Label Image

Container (Image 11)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection in a prefilled syringe, labeled for prescription use. The packaging shows the product name in prominent purple lettering, with active ingredient adalimumab-bwwd indicated. It is distributed by A-S Medication Solutions and includes dosage strength and volume details. The syringe and packaging are visible, highlighting the single-use format.*

FDA Label Image

Figure B (Prefilled Syringe)

An illustration depicts a wristwatch on a person's arm showing the time, accompanied by a syringe with a needle cap. This image likely represents timing related to subcutaneous injection procedures.*

FDA Label Image

Figure C (Prefilled Syringe)

An illustration showing a prefilled syringe, an alcohol swab packet labeled 70% isopropyl, a red sharps container for disposal, and cotton balls or gauze pads. The diagram highlights items used together for subcutaneous injection procedures.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe with solution inside. The image includes reminder check points: confirm the solution is clear, ensure no particles are present, and check the expiration date on the syringe or vial label.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional diagram labeled Figure E showing a human torso with designated injection sites on the abdomen and thighs. The image includes a prompt to clean skin prior to injection with an illustration of an alcohol swab packet.*

FDA Label Image

Figure F (Prefilled Syringe)

Illustration showing two hands preparing a syringe for injection. The left hand holds a syringe cap with an arrow indicating removal, while the right hand holds the syringe barrel with the needle exposed, illustrating proper cap removal technique before subcutaneous injection.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration labeled 'Figure G' showing a hand administering a subcutaneous injection at a 45 degree angle. The image visually demonstrates how to hold the syringe and insert the needle into the skin.*

FDA Label Image

Figure H (Prefilled Syringe)

Illustration showing a hand holding a syringe with a plunger, with the other hand positioned to receive a subcutaneous injection, indicated by an arrow pointing to the pushing action on the plunger. This demonstrates proper injection technique.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe for subcutaneous injection. Text instructions indicate proper dose administration with the needle retracted and no medicine leaked out, except a small drop is acceptable. A sharps container is shown nearby for safe disposal of the syringe.*

FDA Label Image

Samsung Logo (Image 20)

FDA Label Image

Organon Logo (Image 21)

Packaging label showing manufacturing information for HADLIMA 40 mg/0.8 mL solution, subcutaneous injection. The label states it is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure A (Autoinjector)

Illustration labeled as Figure A depicting a syringe with labeled parts including needle cap, base, medicine window, and medicine label.*

FDA Label Image

Refrigerator (Image 23)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection packaging label. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, and the labeler A-S Medication Solutions. The product NDC 50090-6706 is visible on the label.*

FDA Label Image

Light (Image 24)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection vial label by A-S Medication Solutions. The label features the proprietary name HADLIMA prominently in red text, with the generic name adalimumab-bwwd below. The label also includes dosage form and route information, along with regulatory and manufacturing details in smaller text.*

FDA Label Image

Caution (Image 25)

The image shows a vial label for HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The label includes the nonproprietary name adalimumab-bwwd. The labeler is A-S Medication Solutions, and the NDC is 50090-6706. The vial appears to be a single-dose container.*

FDA Label Image

Container (Image 26)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection in a glass vial. The label includes the product name, active ingredient adalimumab-bwwd, strength, dosage form, and manufacturer A-S Medication Solutions. The vial is clear with a green cap and printed label text.*

FDA Label Image

Figure B (Autoinjector)

An instructional diagram labeled Figure B showing a wristwatch on a left wrist and a single-use auto-injector pen for subcutaneous injection. The image illustrates timing or duration related to the use of the injection device, relevant to the administration of HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Figure C (Autoinjector)

Illustration labeled 'Figure C' showing a HADLIMA autoinjector pen along with an alcohol swab packet, a red sharps container, and cotton balls or gauze pads. The note clarifies that the alcohol swab, sharps container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

Illustration showing a hand holding a HADLIMA PouchTouch subcutaneous injection device labeled with expiration date. The image emphasizes checking the solution for clarity and absence of particles before use, as well as verifying the expiration date on the label.*

FDA Label Image

Figure E (Autoinjector)

Figure E is an instructional illustration showing recommended injection sites for subcutaneous administration of HADLIMA (adalimumab-bwwd). It highlights the abdomen and the front thighs as areas for injection, alongside a note to clean the skin with an alcohol swab prior to injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration labeled 'Figure F' showing hands removing the cap from a syringe. The syringe has a green ring near the tip, and a blue arrow indicates the direction to pull the cap off.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration labeled Figure G showing a hand grasping a syringe. An arrow points downward indicating the direction to press, with the word 'Click' and a checkmark to signify confirmation of action.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration labeled Figure H showing a hand holding a device with a vertical yellow marker. The diagram includes a zoomed-in view of the marker and a prompt to "Click," indicating a step in device operation or activation.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a subcutaneous injection device next to a sharp container. The image highlights a yellow medicine window and notes that no medicine leakage is visible, indicating the dose is ready. Text emphasizes proper medication handling and disposal.*

FDA Label Image

Samsung Logo (Image 35)

FDA Label Image

Organon Logo (Image 36)

The label states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA. The image includes the labeler information but does not show the product name, strength, or dosage form.*

FDA Label Image

Figure A (Prefilled Syringe)

An instructional diagram labeled Figure A showing parts of a syringe for subcutaneous injection. The labeled components include the needle cap, body with window, flange, and plunger. The illustration highlights each main syringe part distinctly.*

FDA Label Image

Refrigerator (Image 38)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection packaging label by A-S Medication Solutions. The label includes proprietary and generic names adalimumab-bwwd, dosage details, and administration route. The label design features blue and white color elements with product information displayed clearly on the front panel.*

FDA Label Image

Light (Image 39)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The product label shows the proprietary name HADLIMA prominently, indicating the active ingredient adalimumab-bwwd. Labeled as a human prescription drug, it is distributed by A-S Medication Solutions. The label includes dosage strength and route of administration information.*

FDA Label Image

Caution (Image 40)

The image shows a white carton box for HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The label includes the generic name adalimumab-bwwd and indicates it is a human prescription drug. The product is labeled by A-S Medication Solutions with NDC 50090-6706.*

FDA Label Image

Container (Image 41)

HADLIMA 40 mg/0.8 mL subcutaneous solution packaging label by A-S Medication Solutions. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, and the NDC 50090-6706. It is identified as a human prescription drug.*

FDA Label Image

Figure B (Prefilled Syringe)

Illustration showing a left hand wearing a pink wristwatch next to a prefilled syringe with a needle cover, depicting preparation for subcutaneous injection.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled Figure C depicting a prefilled syringe for subcutaneous injection. It also shows an alcohol swab, a sharps container, and cotton balls or gauze, with a note indicating these items are not included in the carton.*

FDA Label Image

Figure D (Prefilled Syringe)

Illustration labeled 'Figure D' showing a hand holding a syringe with solution. The diagram highlights checking if the solution is clear, ensuring no particles are present, and verifying the expiration date before use.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration labeled 'Figure E' showing a front view of a person with highlighted injection sites on the abdomen and thighs. It includes a reminder to clean the skin before injection and depicts an alcohol swab packet containing 70% isopropyl alcohol.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration labeled Figure F showing two hands: one holding a capped syringe and the other removing or placing the cap, indicated by a blue arrow pointing away from the syringe tip. The image demonstrates part of the preparation process for subcutaneous injection.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing an injection technique where a syringe is held at a 45-degree angle to the skin on a person's arm, demonstrating a subcutaneous injection method.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing a hand holding a prefilled syringe with the other hand positioned for subcutaneous injection. The syringe contains a solution and an arrow indicates the proper finger placement for pressing the plunger.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe near a sharps container. Text indicates you have your dose if the needle is retracted and no medicine has leaked out, noting that a small drop is acceptable.*

FDA Label Image

Samsung Logo (Image 50)

FDA Label Image

Organon Logo (Image 51)

Label indicating the product was manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, New Jersey, USA.*

FDA Label Image

Figure A (Autoinjector)

An illustration labeled Figure A showing parts of a prefilled syringe for subcutaneous injection. It identifies the needle cap, base, medicine window, and medicine label areas from left to right.*

FDA Label Image

Refrigerator (Image 53)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection in a prefilled syringe, labeled by A-S Medication Solutions. The label shows dosage strength, route, proprietary and generic names, and product NDC 50090-6706.*

FDA Label Image

Light (Image 54)

HADLIMA 40 mg/0.8 mL subcutaneous solution packaging label, containing a prefilled syringe. The label shows the proprietary name, adalimumab-bwwd as the active ingredient, dosage form as solution, and strength as 40 mg per 0.8 mL. The labeler is A-S Medication Solutions.*

FDA Label Image

Caution (Image 55)

HADLIMA 40 mg/0.8 mL solution in a prefilled syringe for subcutaneous use. The label displays the proprietary name HADLIMA, the generic name adalimumab-bwwd, and indicates it is a human prescription drug. The product is labeled by A-S Medication Solutions and includes a 0.8 mL dose containing 40 mg of the active ingredient.*

FDA Label Image

Container (Image 56)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection packaging by A-S Medication Solutions. The label shows the product name, strength, dosage form, and administration route, containing one prefilled syringe.*

FDA Label Image

Figure B (Autoinjector)

Illustration showing a wristwatch on a hand indicating the time, positioned next to a subcutaneous injection pen device. This image likely relates to timing or usage instructions for a subcutaneous medication administration.*

FDA Label Image

Figure C (Autoinjector)

Illustration showing the HADLIMA autoinjector pen for subcutaneous injection, accompanied by images of an alcohol swab, sharps container, and cotton ball or gauze, which are noted as not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional illustration showing a hand holding a HADLIMA PushTouch prefilled syringe. It highlights checking the syringe for particles and clarity, and verifying the expiration date before use.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration showing a human torso with shaded injection sites on the abdomen and thighs. Includes a depiction of an alcohol swab packet labeled "70% isopropyl" with the instruction to clean the skin before injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration labeled Figure F, showing hands removing the cap from a prefilled subcutaneous injection pen, depicting the first step in preparing HADLIMA (adalimumab-bwwd) injection for use.*

FDA Label Image

Figure G (Autoinjector)

An instructional diagram labeled Figure G showing a hand holding a pen-like injector device positioned for subcutaneous injection. The image includes an arrow pointing downward indicating the direction of injection and the word 'Click' with a check mark, demonstrating the activation or usage step for administering HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration labeled 'Figure H' showing a hand gripping a pen-like device with a close-up inset of an orange indicator on the device. The word 'Click' with a check mark is shown, indicating the correct positioning or action for the device, likely related to administration or preparation steps.*

FDA Label Image

Figure I (Autoinjector)

Illustration showing a hand holding a prefilled syringe for subcutaneous injection. The image highlights checking that the medicine window is yellow and that no medicine has leaked out, with a sharps container shown nearby for disposal.*

FDA Label Image

Samsung Logo (Image 65)

FDA Label Image

Organon Logo (Image 66)

Packaging label text showing product manufactured for Organon LLC, a subsidiary of Organon & Co., based in Jersey City, NJ, USA.*

FDA Label Image

Figure 3 (Image 72)

Two line graphs labeled Study UV I and Study UV II showing treatment failure rates (%) over 20 months comparing placebo and Humira treatments. Each graph plots treatment failure rate on the y-axis against time in months on the x-axis, with Humira showing lower failure rates than placebo in both studies.*

FDA Label Image

Label Image (Lbl500906706)

Packaging label for HADLIMA PushTouch (adalimumab-bwwd) 40 mg/0.8 mL solution for subcutaneous injection by A-S Medication Solutions. Each dose contains 40 mg adalimumab. The label includes storage instructions and indicates the product comes in a 2 single-dose prefilled auto-injector package. The NDC is 50090-6706-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.